Dengue Vaccine: Rio Starts Immunization & Updates Across Brazil

Rio de Janeiro has initiated a city-wide vaccination campaign against dengue fever, deploying a newly developed vaccine produced by the Butantan Institute. The rollout began on Tuesday, February 24, 2026, initially targeting healthcare workers in primary care settings. This marks a significant step in Brazil’s ongoing efforts to combat the pervasive threat of dengue, a mosquito-borne viral infection that poses a substantial public health challenge, particularly during the warmer months.

The first phase of the vaccination drive prioritizes approximately 100 health facilities – family clinics and municipal health centers – that recorded the highest number of dengue cases throughout 2025. This strategic approach aims to protect those on the front lines of patient care and limit further transmission within the healthcare system. A shipment of 12,500 doses arrived in Rio for the campaign’s launch, with vaccinations commencing at the José Manoel Ferreira Municipal Health Center in Catete, the facility that treated the most dengue cases in the network last year. The vaccine, a single-dose formulation, is approved for individuals aged 15 to 59 who have not previously received a dengue vaccine.

New Butantan Vaccine Offers Broad Protection

The vaccine developed by the Butantan Institute is designed to provide protection against all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4). This broad-spectrum coverage is crucial, as infection with one serotype provides only temporary immunity and can, in some cases, increase the risk of severe illness upon subsequent infection with a different serotype. The National Health Surveillance Agency (Anvisa) has granted approval for the vaccine, underscoring its safety and efficacy. According to Daniel Soranz, Rio’s Municipal Secretary of Health, the vaccine is “safe and 100% Brazilian,” representing a significant achievement for the nation’s public health infrastructure. The Prefeitura do Rio de Janeiro website details the campaign’s initial phases and goals.

The rollout in Rio is part of a larger national plan for dengue vaccination, with the Ministry of Health overseeing the distribution of doses to states and municipalities. Further expansion of the vaccination program to include additional population groups will depend on the availability of future vaccine shipments. The Butantan Institute, a leading biomedical research institution in Brazil, has a long history of developing and producing vaccines for a range of infectious diseases, including influenza and yellow fever. The development of this dengue vaccine represents a major milestone in the institute’s ongoing commitment to public health innovation.

Dengue in Rio and Brazil: A Growing Concern

Dengue fever is a significant public health concern in Brazil, with outbreaks occurring annually, particularly during the rainy season. The virus is transmitted to humans through the bite of infected Aedes aegypti mosquitoes. Symptoms typically include high fever, severe headache, muscle and joint pain, rash, and, in some cases, bleeding. While most cases are mild, dengue can progress to a more severe form known as dengue hemorrhagic fever, which can be life-threatening. G1 reports that, as of 2025, Rio de Janeiro had already registered 9,291 cases of dengue and four related deaths.

The introduction of this new vaccine offers a crucial tool in the fight against dengue, complementing existing prevention strategies such as mosquito control measures, public awareness campaigns, and environmental sanitation. Mosquito control efforts focus on eliminating breeding sites, such as stagnant water in containers, and using insecticides to reduce mosquito populations. Public awareness campaigns aim to educate people about how to protect themselves from mosquito bites, including using insect repellent, wearing long sleeves and pants, and sleeping under mosquito nets.

Vaccine Availability and Eligibility

Currently, the Butantan vaccine is specifically designated for healthcare professionals working in primary care. This initial focus is intended to safeguard the healthcare workforce and ensure the continued provision of essential medical services. The vaccine is a single-dose regimen, simplifying the vaccination process and increasing compliance. Individuals aged 15 to 59 who have not previously been vaccinated against dengue are eligible to receive the vaccine. Although, it is not recommended for pregnant women, individuals with compromised immune systems, or those with a history of severe allergic reactions to vaccine components.

In addition to the Butantan vaccine, the Qdenga vaccine, developed by Takeda, remains available for children and adolescents aged 10 to 14 in Rio de Janeiro. This vaccine requires two doses and is administered at 240 points across the municipal network, including family clinics, health centers, and the Super Centro Carioca de Vacinação. Approximately 206,000 children and adolescents have received the first dose of Qdenga, and 104,000 have completed the full vaccination schedule. This layered approach, utilizing two different vaccines targeting different age groups, aims to maximize population immunity and reduce the burden of dengue in the city.

Sergipe Receives Vaccine Doses

The rollout isn’t limited to Rio de Janeiro. The state of Sergipe has also received a shipment of 7,900 doses of the Butantan dengue vaccine, according to G1. This demonstrates a broader national effort to distribute the vaccine and protect populations across different regions of Brazil.

The successful implementation of the dengue vaccination campaign will require ongoing collaboration between federal, state, and municipal health authorities, as well as active participation from healthcare professionals and the public. Continued monitoring of vaccine coverage, disease incidence, and potential adverse events will be essential to assess the impact of the program and build necessary adjustments. The Butantan Institute’s vaccine represents a beacon of hope in the fight against dengue, offering a new layer of protection for the Brazilian population.

Key Takeaways

• Rio de Janeiro has launched a dengue vaccination campaign using a new vaccine from the Butantan Institute.
• The initial phase targets healthcare workers in primary care settings.
• The vaccine is a single-dose formulation approved for individuals aged 15 to 59.
• Brazil is facing a significant dengue burden, with thousands of cases reported annually.
• The Butantan vaccine protects against all four serotypes of the dengue virus.

The Ministry of Health will continue to provide updates on vaccine distribution and campaign expansion. Individuals are encouraged to consult with their healthcare providers for more information about dengue vaccination and prevention. Stay informed and protect yourself and your community from this potentially serious disease. Share this information with your network to help raise awareness about the importance of dengue prevention and vaccination.